the incidence of drug- resistant mutants in patients with chronic hbv infection after lamivudine treatment

نویسندگان

sepide ezzatpanah fard blood transfusion research center, high institute for research and education in transfusion medicine, tehran, ir iran; department of microbiology, shahid beheshti university of medical sciences, tehran, ir iran

zohreh sharifi blood transfusion research center, high institute for research and education in transfusion medicine, tehran, ir iran; blood transfusion research center, high institute for research and education in transfusion medicine, tehran, ir iran. email:

seyed masoud hosseini department of microbiology, shahid beheshti university of medical sciences, tehran, ir iran

mahmood mahmoodian shooshtari blood transfusion research center, high institute for research and education in transfusion medicine, tehran, ir iran

چکیده

conclusions this study showed that the presence of mutation at codons rtl80v, rtl180m and rtm204v in a, b and c domains is associated with higher viral load and resistance to lamivudine (3tc) respectively. results about 6% (3 of 50) of samples were hbeag positive and 94% (47 of 50) of patients were hbeag negative by elisa method. the patients' alt level was between 16 and 95 iu/l with the mean of 37.58 iu/l. also, 48% (24 of 50) of samples had < 104 iu/ml viral load, 52% (26 of 50) of them had > 104 iu/ml viral load. about 10% (5 of 50) of samples was treated with lamivudine with specific substitution of amino acid located at codons 80, 180 and 204. in addition, phylogenetic tree showed that genotype d of hbv was dominant among iranian hbv infected patients objectives the aim of this study was to investigate rtl180m and rtm204v mutations in polymerase gene of hbv in infected patients after lamivudine therapy. patients and methods fifty sera samples collected from patients who referred to blood transfusion center in tehran were studied. the samples were divided into two groups; treated and untreated based on antiviral treatment status. from 50 patients, 34% were males and 66% were females, aged between 18 and 80 years.rnall of samples were tested for anti hepatitis b e antibody (anti-hbe), hepatitis b e antigen (hbeag), hepatitis b surface antigen (hbsag) and hepatitis b core antibody (anti-hbc) by enzyme-linked immunosorbent assay (elisa) method. the alt levels were measured using a commercial kit. then hbv-dna was extracted from serum samples using a commercial kit and a fragment of the p gene was amplified by nested pcr. also, hbv viral load was detected by real-time pcr. hbv genotypes and polymerase gene mutations were determined by direct sequencing of the polymerase gene of hbv. phylogenetic tree was constructed using neighbor-joining (nj) method. background hepatitis b virus (hbv) is replicated through reverse transcription of polymerase gene. lamivudine can postpone the clinical progression in hepatitis b infected patients, but the long-term monotherapy causes the emerge of ymdd (tyrosine-methionine-aspartate-aspartate), llaq (leucine–leucine–alanine–glutamine) motifs and increases the alanine aminotransferase (alt) and hbv dna levels.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Identification of Drug Resistant Mutants of HBV (Hepatitis B Virus) by Direct Sequencing in Iranian Patients Treated with Lamivudine

Background and Aims: lamivudine is amongst the antiviral for drug chronic hepatitis B treatment. During therapy with lamivudine, variants may emerge with YMDD mutation in the reverse transcriptase (RT) region of polymerase gene. This mutation might have a role in drug resistant for HBV. Materials and Methods: HBV DNA extraction from serum sample of 88 patients, were subjected to nested PCR for ...

متن کامل

identification of drug resistant mutants of hbv (hepatitis b virus) by direct sequencing in iranian patients treated with lamivudine

background and aims: lamivudine is amongst the antiviral for drug chronic hepatitis b treatment. during therapy with lamivudine, variants may emerge with ymdd mutation in the reverse transcriptase (rt) region of polymerase gene. this mutation might have a role in drug resistant for hbv. materials and methods: hbv dna extraction from serum sample of 88 patients, were subjected to nested pcr for ...

متن کامل

Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.

BACKGROUND Here, we investigated the treatment response and evolution of HBV resistance during lamivudine (LAM) plus adefovir (ADV) and entecavir (ETV) monotherapy in patients with ADV-resistant mutants. METHODS Of the 53 patients with ADV-resistant mutants, 25 received combined LAM plus ADV therapy (LAM+ADV group) and 28 received ETV monotherapy (ETV group) for at least 12 months (median 24 ...

متن کامل

YMDD and FLLAQ Mutations in Chronic Hepatitis B Patients

Abstract Background and Objective: Lamivudine is the first orally available drug approved for treatment of chronic hepatitis B. Mutations at the YMDD and FLLAQ motifs in the domains of HBV polymerase gene contribute resistance to lamivudine. This study was aimed to determine the rate of YMDD and FLLAQ mutants in hepatitis B patients in Golestan Province, Iran. Material and methods: In this cros...

متن کامل

Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China

In China, HIV-1-infected patients typically receive antiretroviral therapy (ART) that includes lamivudine (3TC) as a reverse-transcriptase inhibitor (RTI) (ART-3TC). Previous studies from certain developed countries have shown that, in ART-3TC, 3TC-resistant HBV progressively emerges at an annual rate of 15-20% in patients coinfected with HIV-1 and HBV. This scenario in China warrants investiga...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
jundishapur journal of microbiology

جلد ۶، شماره ۸، صفحات ۰-۰

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023